Canadian Bronchiolitis Epinephrine Steroid Trial

Conditions

Bronchiolitis Respiratory Bronchiolitis

Larry Dong, Terry P. Klassen, David W. Johnson, Rhonda Correll, Serge Gouin et al. (13 authors)

PLoS ONE2025-05-16

10.1371/journal.pone.0318853

Risk of asthma in children diagnosed with bronchiolitis during infancy: protocol of a longitudinal cohort study linking emergency department-based clinical data to provincial health administrative databases

Kawsari Abdullah, Deshayne B. Fell, Dhenuka Radhakrishnan, Steven Hawken, David W. Johnson et al. (9 authors)

BMJ Open2021-05-012 citations

10.1136/bmjopen-2021-048823

Epinephrine and dexamethasone in children with bronchiolitis.

Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, Mitton C, Gouin S, Bhatt M, Joubert G, Black KJ, Turner T, Whitehouse S, Klassen TP, Pediatric Emergency Research Canada (PERC).

2009-05-01166 citations

10.1056/nejmoa0900544

Interventions

1. Oral dexamethasone 2. Nebulised epinephrine Trial details received: 12 Sept 2005

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 6 weeks to 12 months, either sex 2. Respiratory distress assessment instrument (RDAI) score of greater than 3 and less than 15 3. Diagnosis of bronchiolitis

Exclusion criteria

Exclusion criteria: 1. Asthma or any previous episode of wheezing treated with bronchodilators 2. Chronic cardiopulmonary disease 3. Presence of varicella or recent close contact 4. Severe respiratory distress 5. Recent treatment with oral or inhaled steroids 6. Insurmountable language barrier 7. Any child born at less than 37 weeks gestation who is less than 6 weeks corrected age

Design outcomes

Primary

Measure	Time frame
Admission to hospital up to 7 days after enrolment	—

Secondary

Measure	Time frame
1. Time to discharge 2. Length and severity of symptoms 3. Change in RDAI 4. Economic costs 5. Change in oxygen saturation from baseline at times 60, 120, 180 and 240 minutes 6. Co-interventions 7. Return to be evaluated by health care provider for on-going symptoms related to bronchiolitis 8. Adverse events	—

Countries

Canada

Outcome results

None listed